Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708431 | 1.00 | ROCK2 (0.42) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| SCHEMBL1707074 | 0.95 | SIGMAR1 (0.40) | ROCK2CCR2ROCK1CCR3PDPK1 | |
| SCHEMBL1707075 | 0.95 | SIGMAR1 (0.40) | ROCK2CCR2ROCK1CCR3PDPK1 | |
| SCHEMBL1707637 | 0.92 | ROCK2 (0.41) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| SCHEMBL1707635 | 0.92 | ROCK2 (0.41) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL1707329 | 0.91 | ROCK2 (0.40) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL1707327 | 0.91 | ROCK2 (0.40) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL1707276 | 0.91 | ROCK2 (0.40) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| SCHEMBL1707646 | 0.91 | ROCK2 (0.40) | ROCK2CCR2ROCK1LTA4HCCR3 | |
| SCHEMBL1706817 | 0.89 | SLC6A3 (0.43) | CCR3MAPK1KDM4EATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981877-B1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1981877-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091703-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC6, HDAC5 | ROCK2 1869/4885CCR2 2338/4885ROCK1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.